echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Which cancer patients is suitable for proton therapy?

    Which cancer patients is suitable for proton therapy?

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Compared with the high mortality rate, the early detection rate of liver cancer is very low

    There are many treatment methods for liver cancer, such as surgery, intervention, and radiotherapy, but the effect is still not very satisfactory

    According to statistics from many international proton therapy centers, the 5-year local control rate of proton therapy for liver cancer exceeds 80%

    A new choice of radiotherapy for liver cancer-proton therapy 

    The essence of proton therapy is radiotherapy, but the difference is that it uses proton rays to accurately irradiate the tumor

    Liver cancer is not very sensitive to radiation therapy.

    Proton therapy is better than ordinary radiotherapy

    Secondly, the Bragg peak is formed when proton rays irradiate the tumor



    Comparison of x-ray and proton therapy for liver cancer

    X-rays release energy when they reach the human skin

    The advantage of proton therapy is that compared with other treatment methods, it can achieve a higher treatment response rate, the tumor control rate is above 90%, and it will not reduce liver function and increase the side effects on the gastrointestinal tract


    For early liver cancer, proton therapy has similar results as surgery or percutaneous ablation

     In Japan, where the incidence of liver cancer is also high, the University of Tsukuba has used protons to treat liver cancer patients since 1985

    The treatment results showed that the 5-year local control rate (LC) was 86.

    In addition, a recent new long-term follow-up by the University of Tsukuba (median follow-up 55 months) showed that the 5-year local control rate (LC) of patients with stage 0/a, B and C were 94%, 87%, and 75%, respectively

    This study also confirmed that the results of proton therapy in patients with stage 0/A are similar to the results of partial hepatectomy or percutaneous ablation

    For larger liver cancers, proton therapy is more appropriate

    If hepatocellular carcinoma (HCC) patients are more likely to develop radiation liver disease after receiving SBRT (stereotactic radiotherapy), proton therapy may be more appropriate

    A study treated 22 HCC patients with a median tumor size of 11 cm (10 to 14 cm), with a radiation dose of 72.

    Elderly patients with liver cancer are also suitable for proton therapy

    A study by the University of Tsukuba included 21 patients with a median age of 81 years (80 to 85 years)

    This study confirms that elderly patients can also obtain good therapeutic effects through proton therapy

    Appropriately increasing the dose of proton therapy can improve the therapeutic effect and prolong survival

    In 2005, researchers from Chiba Prefecture, Japan reported that after patients received proton therapy with a median dose of 76 GyE/20 f, 80% of 30 patients achieved complete radiation remission, and the 2-year local control rate (LC) was 96%

    The Hyogo Prefecture Ion Medicine Center retrospectively analyzed 242 patients who received 8 proton therapy programs (52.
    8~84gye /4~38f), the 5-year local control rate (LC) was 90%, and the 5-year overall survival rate (OS) Is 38%

    Researchers at MD Anderson Cancer Center recently reported the results of a retrospective analysis of 46 patients who received proton therapy with different segmentation schemes, including radiation doses of 58 GyE/15 f and 67.
    5 GyE/15 f (56%)
    They pointed out that for patients with a bioequivalent dose (BED) ≥90 GyE, the median overall survival increased from 15.
    8 months to 49.
    9 months, indicating a dose-response effect

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.